A Phase 2 interventional study of bremelanotide in Female Sexual Arousal Disorder and Hypoactive Sexual Desire Disorder, sponsored by Palatin Technologies, Inc. Completed at 68 sites in 2 countries. Open to female participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2014-12-18.
Sponsored by Palatin Technologies, Inc · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 62 studies in Sexual Dysfunctions, Psychological with a site in United States — 3 open to participants now, 6 under way, none of them phase 3. Sexual Dysfunctions, Psychological · United States.
Among the 62 studies in Sexual Dysfunctions, Psychological with a site in United States, this one is the 15th largest by enrollment of the 59 interventional ones that give a count, is one of 3 that started in 2011, is one of 13 in phase 2, and was the 30th registered.
138 studies on the registry are indexed under Sexual Dysfunctions, Psychological; 10 are open to participants now.
Browse Sexual Dysfunctions, Psychological studies →3 of the 62 studies in Sexual Dysfunctions, Psychological with a site in United States are open now. Recruiting first, the newest first:
Urological Research Network, LLC · Sites in United States
Ages 50–80 · Men only · Healthy volunteers
University of Illinois at Chicago · Sites in United States
Ages 18+ · Women only
San Diego Sexual Medicine · Sites in United States
Ages 21–75 · Women only · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 5 Sexual Dysfunctions, Psychological studies recruiting now, 2 set no upper age limit and 1 stops at 75 or younger; none take children under 18; 2 take healthy volunteers.
This study: 21 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
62 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 16 · Phase 3 27 · Phase 4 2
First in 2002; this study’s year is marked. 3 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 612 is above the median of 100 across 114 interventional studies indexed under Sexual Dysfunctions, Psychological.
Median enrollment 196 across the 59 interventional studies, 18 across the 1 observational. Of the 53 that completed or were terminated, 20 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
39 of 62 have an industry lead sponsor. The 10 most frequent:
Palatin Technologies, Inc is the lead sponsor of 11 studies on the registry; none are open to participants now.
Palatin Technologies, Inc has 4 studies filed under Sexual Dysfunctions, Psychological — fewer than ten, so there is no comparison to draw.
2 of the studies in Sexual Dysfunctions, Psychological with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05777031University of MiamiSafety and Efficacy of Collagenase Clostridium Histolyticum After Prior Intralesional PRP for Peyronie's Disease | 2027-01-15 |
| NCT06458049Dana-Farber Cancer InstituteSexual Health and Rehabilitation Online (SHAREonline) | 2027-05-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 62 studies in Sexual Dysfunctions, Psychological with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This trial is designed to evaluate the efficacy and safety of 3 fixed dose levels of bremelanotide, administered subcutaneously on an as-needed basis under conditions of home use, for the treatment of female sexual arousal disorder (FSAD), hypoactive sexual desire disorder (HSDD), or mixed FSAD/HSDD in premenopausal women.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Female, at least 21 years of age, and premenopausal Previously experienced sexual arousal during sexual activity and/or normal level of desire in the past for least 2 years.
Willing to engage in sexual activities Currently in stable relationship with a partner(male or female)for at least 6 months.
If subject has a male sexual partner, has recorded a score of "not impotent" or "minimally impotent" on Single-question Assessment of ED.
For at least 6 months before Screening, has met diagnostic criteria for FSAD, HSDD, or mixed FSAD/HSDD Has a negative serum pregnancy test (hCG) at Screening and, if subject's partner is male, has used a medically acceptable form of for the 3 months before Screening (Visit 1), and is willing to continue for the duration of the trial and 1 month following the last dose of trial drug.
Has a normal pelvic examination. At Screening or documented within 12 months before Screening, has:normal Pap test results with or without history of positive HPV, dysplasia, or ASCUS that has resolved or been treated;Pap test results positive for ASCUS and negative for HPV;Pap test results positive for HPV AND no ASCUS or dysplasia on Pap or condyloma present upon examination.
At Screening and Visit 2, meets all necessary questionnaire scores.
Exclusion Criteria:
Medical condition that is unstable or uncontrolled despite current therapy. History of unresolved sexual trauma or abuse. Pregnant or nursing. Lifelong anorgasmia, vaginismus, sexual pain disorder, sexual aversion disorder, or persistent sexual arousal disorder.
Female sexual dysfunction caused by untreated endocrine disease. Has or has had any of the following: , other infectious hepatitis, infectious blood disorders such as ; myocardial infarction;stroke.
Has or has had any of the following within 12 months before Screening:chronic dyspareunia not attributable to vaginal dryness; pelvic inflammatory disease; chronic or complicated UTI, or an active STD other than herpes and condyloma; cervical dysplasia, including LGSIL and HGSIL and/or ASCUS with HPV; significant cervicitis as manifested by mucopurulent discharge from the cervix.
Has had any of the following within 6 months before Screening:≥ 2 outbreaks of genital herpes; occurrence/recurrence of condyloma;clinically unstable angina or clinically unstable arrhythmia;significant CNS diseases; or ALT concentrations > 3 times the ;serum creatinine > 2.5 mg/dL;any other clinically significant abnormal laboratory result.
Has used prohibited medications within the 3 months before Screening:
Has currently active moderate to severe vaginitis or a clinically significant vaginal infection.
Has one or more significant gynecologic conditions . Is taking or has received treatment for psychosis, bipolar disorder, depression, and/or alcohol/substance abuse within 6 months before Screening.
Is currently receiving psychotherapy for the treatment of FSAD and/or HSDD. Has any of the following: Uncontrolled hypertension;Systolic BP of ≥ 140 mm Hg at Screening;Diastolic BP of ≥ 90 mm Hg at Screening; Treatment for hypertension that has changed in the 3 months before Screening.
Had a hysterectomy with bilateral oophorectomy. Had a hysterectomy without bilateral oophorectomy AND meets several other criteria.
Is taking that have affected the menstrual cycle or caused amenorrhea AND did not have a normal menstrual cycle before starting the contraceptive medication.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Same formulation as the investigation product but without the active ingredient, provided as pre-filled syringes containing 0.3 mL volume. Subjects will self-administer the placebo by SC injection in the same manner as the investigational product.
Drug: bremelanotide
Low dose: Investigational product: Bremelanotide aqueous solution for subcutaneous (SC) injection, provided as pre-filled syringes containing 0.75 mg in 0.3 mL volume. Subjects will self-administer bremelanotide by SC injection into the anterior thigh or abdomen.
Drug: bremelanotide
Middle dose: Investigational product: Bremelanotide aqueous solution for subcutaneous (SC) injection, provided as pre-filled syringes containing 1.25 mg in 0.3 mL volume. Subjects will self-administer bremelanotide by SC injection into the anterior thigh or abdomen.
Drug: bremelanotide
High dose: Investigational product: Bremelanotide aqueous solution for subcutaneous (SC) injection, provided as pre-filled syringes containing 1.75 mg in 0.3 mL volume. Subjects will self-administer bremelanotide by SC injection into the anterior thigh or abdomen.
Drug: bremelanotide
Subjects will administer drug on an as needed basis, prior to anticipated sexual activity. Investigational product: Bremelanotide aqueous solution for subcutaneous (SC) injection, provided as pre-filled syringes containing 0.75, 1.25, or 1.75 mg in 0.3 mL volume. Subjects will self-administer bremelanotide by SC injection into the anterior thigh or abdomen. Placebo: Same formulation as the investigation product but without the active ingredient, provided as pre-filled syringes containing 0.3 mL volume. Subjects will self-administer the placebo by SC injection in the same manner as the investigational product.
Also known as: PT-141
The Primary Efficacy Endpoint is Change From Baseline to End of Study in the Number of Satisfying Sexual Events (SSE)
The primary efficacy endpoint is change from baseline to end of study in the number of satisfying sexual events (SSEs), computed as the number of events during the last 4 weeks of treatment with FSEP-R Q10 = "Yes" minus the number of baseline events with FSEP-R Q10 = "Yes." Efficacy analyses were done with the MITT population which consisted of all randomized subjects who took at least 1 dose of double-blind treatment after the 2 in-clinic doses of double-blind medication and who had at least 1 follow-up visit (Visit 10 or later) to ensure that FSEP-R data were reviewed and confirmed by the investigative site.
Time frame: 4 - 12 weeks from baseline to end of study (total study duration 20 weeks). Baseline was the 4-week single-blind placebo period.
Change From Baseline to End-of-Study in Arousal Domain Score From Female Sexual Function Index
The FSFI is brief self-report questionnaire that measures female sexual function. The change from baseline to end of study in the arousal domain were obtained from the FSFI Q3 through Q6. The score range is 0-5. For each of the 2 time points, the score was computed programmatically using the algorithm described by Rosen \[6\], resulting in a score from 0 (min) to 6 (max).
Time frame: 4-12 weeks from baseline to end of study (total study duration 20 weeks)
Satisfaction With Arousal as Measured by GAQ Question 1
This is the change in Baseline to End-of-Study in Satisfaction with Arousal as measured by GAQ Question 1. GAQ (Global Assessment Questions) is a questionnaire that evaluates overall satisfaction level experienced while using the study drug. Question 1 is "Compared to the start of the study (prior to taking the study drug), how would you describe your satisfaction with your arousal while using the study drug?" The score range is 1 (very much worse) to 7 (very much better).
Time frame: 4-12 weeks from baseline to end of study (total study duration 20 weeks)
Desire Domain From Female Sexual Function Index
The FSFI is brief self-report questionnaire that measures female sexual function. The change from baseline to end of study in the desire domain were obtained from the FSFI Q1 and Q2. The score range is 1-5. For each of the 2 time points, the score was computed programmatically using the algorithm described by Rosen \[6\], resulting in a score from 0 (min) to 6 (max).
Time frame: 4-12 weeks from baseline to end of study (total study duration 20 weeks)
Satisfaction With Desire as Measured by GAQ Question 2
This is the change in Baseline to End-of-Study in Satisfaction with Desire as Measured by GAQ Question 2. GAQ (Global Assessment Questions) is a questionnaire that evaluates overall satisfaction level experienced while using the study drug. Question 2 is "Compared to the start of the study (prior to taking the study drug), how would you describe your satisfaction with your desire while using the study drug?" The score range is 1 (very much worse) to 7 (very much better).
Time frame: 4-12 weeks from baseline to end of study (total study duration 20 weeks)
Quality of Relationship With Partner as Measured by GAQ Question 4
This is the change in Baseline to End-of-Study in Quality of Relationship with Partner as Measured by GAQ Question 4. GAQ (Global Assessment Questions) is a questionnaire that evaluates overall satisfaction level experienced while using the study drug. Question 4 is "Compared to the start of the study (prior to taking the study drug), how has taking the study drug changed your relationship with your partner?" The score range is 1 (very much worse) to 7 (very much better).
Time frame: 4-12 weeks from baseline to end of study (total study duration 20 weeks)
FSDS-DAO Total Score
FSDS-DAO (Female Sexual Distress Scale - Desire/Arousal/Orgasm) is an assessment tool to measure female sexual distress. The change from baseline to end of study in the FSDS-DAO (total score) was measured. There are 15 questions, eg, "How often do you feel: Distressed about your sex life" and the score range was 0 (Never), 1 (Rarely), 2 (Occasionally), 3 (Frequently), 4 (Always). The score for each subject at each time point was computed as the sum of the scores from the 15 questions, resulting in a possible score at each time point between 0 and 60.
Time frame: 4 - 12 weeks from baseline to end of study (total study duration 20 weeks)
A total of 1142 subjects were screened at 69 medical sites in the US and Canada, 612 subjects were enrolled, and 488 subjects entered the single-blind placebo treatment period; 397 were randomized, and 394 were dosed with randomized treatment.
| Milestone | Placebo | Bremelanotide Arm 1 | Bremelanotide Arm 2 | Bremelanotide Arm 3 |
|---|---|---|---|---|
| Started | 98 | 100 | 100 | 99 |
| Subjects not dosed | 1 | 0 | 1 | 1 |
| Completed | 80 | 81 | 66 | 66 |
| Not completed | 18 | 19 | 34 | 33 |
The primary efficacy endpoint is change from baseline to end of study in the number of satisfying sexual events (SSEs), computed as the number of events during the last 4 weeks of treatment with FSEP-R Q10 = "Yes" minus the number of baseline events with FSEP-R Q10 = "Yes." Efficacy analyses were done with the MITT population which consisted of all randomized subjects who took at least 1 dose of double-blind treatment after the 2 in-clinic doses of double-blind medication and who had at least 1 follow-up visit (Visit 10 or later) to ensure that FSEP-R data were reviewed and confirmed by the investigative site.
| SSEs | Placebo | Bremelanotide Arm 1 | Bremelanotide Arm 2 | Bremelanotide Arm 3 |
|---|---|---|---|---|
| The Primary Efficacy Endpoint is Change From Baseline to End of Study in the Number of Satisfying Sexual Events (SSE) | 0.2 ± 2.29 | 0.6 ± 3.55 | 0.7 ± 1.81 | 0.8 ± 2.86 |
The FSFI is brief self-report questionnaire that measures female sexual function. The change from baseline to end of study in the arousal domain were obtained from the FSFI Q3 through Q6. The score range is 0-5. For each of the 2 time points, the score was computed programmatically using the algorithm described by Rosen \[6\], resulting in a score from 0 (min) to 6 (max).
| units on a scale | Placebo | Bremelanotide Arm 1 | Bremelanotide Arm 2 | Bremelanotide Arm 3 |
|---|---|---|---|---|
| Change From Baseline to End-of-Study in Arousal Domain Score From Female Sexual Function Index | 0.51 ± 1.371 | 0.35 ± 1.457 | 0.71 ± 1.112 | 1.06 ± 1.146 |
This is the change in Baseline to End-of-Study in Satisfaction with Arousal as measured by GAQ Question 1. GAQ (Global Assessment Questions) is a questionnaire that evaluates overall satisfaction level experienced while using the study drug. Question 1 is "Compared to the start of the study (prior to taking the study drug), how would you describe your satisfaction with your arousal while using the study drug?" The score range is 1 (very much worse) to 7 (very much better).
| units on a scale | Placebo | Bremelanotide Arm 1 | Bremelanotide Arm 2 | Bremelanotide Arm 3 |
|---|---|---|---|---|
| Satisfaction With Arousal as Measured by GAQ Question 1 | 0.4 ± 1.37 | 0.3 ± 1.43 | 0.5 ± 1.46 | 0.9 ± 1.18 |
The FSFI is brief self-report questionnaire that measures female sexual function. The change from baseline to end of study in the desire domain were obtained from the FSFI Q1 and Q2. The score range is 1-5. For each of the 2 time points, the score was computed programmatically using the algorithm described by Rosen \[6\], resulting in a score from 0 (min) to 6 (max).
| units on a scale | Placebo | Bremelanotide Arm 1 | Bremelanotide Arm 2 | Bremelanotide Arm 3 |
|---|---|---|---|---|
| Desire Domain From Female Sexual Function Index | 0.39 ± 1.075 | 0.33 ± 1.093 | 0.55 ± 0.794 | 0.95 ± 1.003 |
This is the change in Baseline to End-of-Study in Satisfaction with Desire as Measured by GAQ Question 2. GAQ (Global Assessment Questions) is a questionnaire that evaluates overall satisfaction level experienced while using the study drug. Question 2 is "Compared to the start of the study (prior to taking the study drug), how would you describe your satisfaction with your desire while using the study drug?" The score range is 1 (very much worse) to 7 (very much better).
| units on a scale | Placebo | Bremelanotide Arm 1 | Bremelanotide Arm 2 | Bremelanotide Arm 3 |
|---|---|---|---|---|
| Satisfaction With Desire as Measured by GAQ Question 2 | 0.4 ± 1.31 | 0.3 ± 1.32 | 0.8 ± 1.44 | 0.9 ± 1.20 |
This is the change in Baseline to End-of-Study in Quality of Relationship with Partner as Measured by GAQ Question 4. GAQ (Global Assessment Questions) is a questionnaire that evaluates overall satisfaction level experienced while using the study drug. Question 4 is "Compared to the start of the study (prior to taking the study drug), how has taking the study drug changed your relationship with your partner?" The score range is 1 (very much worse) to 7 (very much better).
| units on a scale | Placebo | Bremelanotide Arm 1 | Bremelanotide Arm 2 | Bremelanotide Arm 3 |
|---|---|---|---|---|
| Quality of Relationship With Partner as Measured by GAQ Question 4 | 0.3 ± 1.20 | 0.3 ± 1.24 | 0.4 ± 1.22 | 0.6 ± 1.22 |
FSDS-DAO (Female Sexual Distress Scale - Desire/Arousal/Orgasm) is an assessment tool to measure female sexual distress. The change from baseline to end of study in the FSDS-DAO (total score) was measured. There are 15 questions, eg, "How often do you feel: Distressed about your sex life" and the score range was 0 (Never), 1 (Rarely), 2 (Occasionally), 3 (Frequently), 4 (Always). The score for each subject at each time point was computed as the sum of the scores from the 15 questions, resulting in a possible score at each time point between 0 and 60.
| units on a scale | Placebo | Bremelanotide Arm 1 | Bremelanotide Arm 2 | Bremelanotide Arm 3 |
|---|---|---|---|---|
| FSDS-DAO Total Score | -6.8 ± 13.57 | -7.4 ± 13.47 | -9.2 ± 10.79 | -13.1 ± 12.93 |
Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 3/97 (3.1%) | 49/97 (50.5%) |
| Bremelanotide Arm 1 | — | 1/100 (1%) | 64/100 (64%) |
| Bremelanotide Arm 2 | — | 1/99 (1%) | 61/99 (61.6%) |
| Bremelanotide Arm 3 | — | 1/98 (1%) | 67/98 (68.4%) |
| Event | Placebo | Bremelanotide Arm 1 | Bremelanotide Arm 2 | Bremelanotide Arm 3 |
|---|---|---|---|---|
| Escherichia bacteremiaInfections and infestations | 1/97 | 0/100 | 0/99 | 0/98 |
| Intervertebral disc protrusionMusculoskeletal and connective tissue disorders | 1/97 | 0/100 | 0/99 | 0/98 |
| MenometrorrhagiaReproductive system and breast disorders | 1/97 | 0/100 | 0/99 | 0/98 |
| Chest painCardiac disorders | 0/97 | 0/100 | 0/99 | 1/98 |
| Incisional herniaSurgical and medical procedures | 0/97 | 0/100 | 1/99 | 0/98 |
| AsthmaRespiratory, thoracic and mediastinal disorders | 0/97 | 1/100 | 0/99 | 0/98 |
| Event | Placebo | Bremelanotide Arm 1 | Bremelanotide Arm 2 | Bremelanotide Arm 3 |
|---|---|---|---|---|
| NauseaGastrointestinal disorders | 3/97 | 18/100 | 22/99 | 24/98 |
| FlushingVascular disorders | 0/97 | 17/100 | 15/99 | 17/98 |
| HeadacheNervous system disorders | 3/97 | 9/100 | 10/99 | 15/98 |
| Vag hemorrh/discharge, breast tend/mass, metrorrhagia, menstru irreg, genit discomfort/order (1% ea)Reproductive system and breast disorders | 7/97 | 3/100 | 4/99 | 9/98 |
| Upper respiratory tract infectionInfections and infestations | 4/97 | 9/100 | 5/99 | 4/98 |
| Injection/vessel puncture site hematoma (1% each)General disorders | 1/97 | 5/100 | 8/99 | 4/98 |
| Urinary tract infectionInfections and infestations | 1/97 | 7/100 | 8/99 | 0/98 |
| CPK/glu/lipase/chol/BP/triglycerides increased, iron decreased, MCV abnormal (1% each)Investigations | 3/97 | 8/100 | 4/99 | 5/98 |
| Fungal infect, gastroenter/bronchitis, vulvo/vaginitis, follicul/pharyngitis, tooth abcess (1% each)Infections and infestations | 7/97 | 7/100 | 4/99 | 7/98 |
| Injection site painGeneral disorders | 3/97 | 6/100 | 6/99 | 7/98 |
| Age, Continuous(years) | Placebo | Bremelanotide Arm 1 | Bremelanotide Arm 2 | Bremelanotide Arm 3 | Total |
|---|---|---|---|---|---|
| Mean | 37.0 ± 7.70 | 37.6 ± 7.76 | 35.7 ± 7.22 | 37.0 ± 7.56 | 36.9 ± 7.57 |
| Sex: Female, Male(Participants) | Placebo | Bremelanotide Arm 1 | Bremelanotide Arm 2 | Bremelanotide Arm 3 | Total |
|---|---|---|---|---|---|
| Female | 97 | 100 | 99 | 98 | 394 |
| Male | 0 | 0 | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Placebo | Bremelanotide Arm 1 | Bremelanotide Arm 2 | Bremelanotide Arm 3 | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 2 | 1 | 1 | 1 | 5 |
| Asian | 0 | 0 | 0 | 2 | 2 |
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 0 | 0 | 1 |
| Black or African American | 19 | 25 | 32 | 23 | 99 |
| White | 75 | 71 | 65 | 70 | 281 |
| Other | 0 | 3 | 0 | 2 | 5 |
| Unknown or Not Reported | 0 | 0 | 1 | 0 | 1 |
| Weight(Pound) | Placebo | Bremelanotide Arm 1 | Bremelanotide Arm 2 | Bremelanotide Arm 3 | Total |
|---|---|---|---|---|---|
| Mean | 164.40 ± 42.050 | 168.17 ± 37.867 | 173.97 ± 43.229 | 179.15 ± 45.872 | 171.41 ± 42.532 |
| Body Mass Index(kg/m2) | Placebo | Bremelanotide Arm 1 | Bremelanotide Arm 2 | Bremelanotide Arm 3 | Total |
|---|---|---|---|---|---|
| Mean | 27.73 ± 6.171 | 28.47 ± 6.616 | 29.17 ± 7.096 | 29.92 ± 7.181 | 28.82 ± 6.802 |
| Of Childbearing Potential(Participants) | Placebo | Bremelanotide Arm 1 | Bremelanotide Arm 2 | Bremelanotide Arm 3 | Total |
|---|---|---|---|---|---|
| Of Childbearing Potential | 72 | 76 | 70 | 65 | 283 |
| Surgically Sterile | 25 | 24 | 29 | 32 | 110 |
| Data Missing | 0 | 0 | 0 | 1 | 1 |
| Weight Quartile(Pound) | Placebo | Bremelanotide Arm 1 | Bremelanotide Arm 2 | Bremelanotide Arm 3 | Total |
|---|---|---|---|---|---|
| 95 - 143 pounds | 37 | 21 | 23 | 21 | 102 |
| >143 - 165 pounds | 18 | 36 | 25 | 24 | 103 |
| >165 - 200.6 pounds | 23 | 26 | 28 | 24 | 101 |
| >200.6 - 350 pounds | 19 | 17 | 23 | 28 | 87 |
| Data Missing | 0 | 0 | 0 | 1 | 1 |
| Menses Frequency(Participants) | Placebo | Bremelanotide Arm 1 | Bremelanotide Arm 2 | Bremelanotide Arm 3 | Total |
|---|---|---|---|---|---|
| Variable cycle length (<7 days different from nor | 3 | 4 | 4 | 4 | 15 |
| Regular | 72 | 75 | 86 | 79 | 312 |
| Variable cycle length (>7 days different from nor | 7 | 2 | 1 | 2 | 12 |
| 2 or more skipped cycles, and amenorrhea for 60 or | 2 | 6 | 2 | 1 | 11 |
| N.A. | 13 | 13 | 6 | 12 | 44 |
3 further baseline measures are reported on the registry.
The record gives a start of Jun 2011, a primary completion of Sep 2012 and a completion of Sep 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2014, 1 year 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Bremelanotide
Sexual Dysfunctions, Psychological →
Palatin Technologies, Inc